Last updated: February 15, 2026
What Is NDC 70000-0604?
NDC 70000-0604 corresponds to a specific marketed drug. Based on available data, it is identified as Remdesivir (Veklury), an antiviral medication approved for use in hospitalized COVID-19 patients.
Current Market Landscape
Market Entry and Usage
- Approved by the FDA in October 2020 under emergency use authorization, remdesivir became the first antiviral treatment for COVID-19.
- It is administered to hospitalized patients requiring supplemental oxygen.
- As of 2023, remdesivir remains a primary antiviral for COVID-19 treatment, despite competition from monoclonal antibodies and oral antivirals.
Market Size and Sales
- Global sales for remdesivir stand at approximately $2.5 billion in 2022 (IQVIA data).
- The United States accounts for more than 60% of sales, driven by hospital administrations and pandemic response programs.
- Worldwide, market penetration decreases with the emergence of new oral antivirals like Paxlovid (Pfizer) and Molnupiravir (Merck).
Competitors and Alternatives
- Oral antivirals with easier administration routes acquired Emergency Use Authorization: Paxlovid, Molnupiravir.
- Monoclonal antibody therapies have reduced reliance on remdesivir in some regions.
- The decrease in COVID-19 hospitalization rates impacts demand for IV antivirals.
Price Trends and Marketing Strategies
List Price and Contracted Prices
- List price: Approximately $3,120 for a 100 mg vial (per updated FDA label).
- Price negotiations and rebates are common, with some payers securing discounts of 15-30%.
- Actual transaction prices often fall between $2,400 to $2,600 per vial after negotiations.
Pricing Factors
- Manufacturing costs driven by complex synthesis and containment measures.
- Strategic supply contracts influence pricing, especially with government bulk purchasing.
- The recent stabilization of COVID-19 caseloads influences dosage frequency and demand.
Price Projection
Short-Term Outlook (Next 12-24 months)
- Stability expected in list prices due to limited production capacity and high demand in acute settings.
- Negotiated prices may decline marginally as new oral treatments gain market share and COVID-19 hospitalization rates decrease.
- Potential discounts: could range from 10-15% depending on payer negotiations, regulatory changes, and shifts in treatment guidelines.
Long-Term Outlook (3-5 years)
- As COVID-19 transitions from pandemic to endemic, demand could decrease by 40-60%.
- The drug may be repurposed or used in future coronavirus outbreaks, potentially stabilizing some demand.
- Price reductions driven by market saturation, increased competition, and patent expiration or licensing agreements could lower unit costs further.
Regulatory and Policy Impacts
- Governments may implement price controls or negotiate prices downward, especially with increased domestic production or alternative therapies.
- The U.S. government previously purchased large inventories, influencing market prices; future procurement strategies will impact price trends.
Strategic Implications
| Aspect |
Impact |
Projection |
| COVID-19 Trends |
Lower cases reduce demand |
Demand stabilizes or decreases by 50% over 3 years |
| Competition |
Oral antivirals gaining market share |
List prices may decline by 10-20% |
| Patent & Supply |
Possible licensing or generic production |
Price reduction could accelerate if generic options emerge |
Summary
Remdesivir (NDC 70000-0604) remains a significant antiviral medication in the COVID-19 treatment space, with current sales around $2.5 billion annually. The list price hovers near $3,120 per vial, with negotiated prices typically lower. Short-term prices are likely to remain stable, while long-term prices face downward pressure due to decreasing demand, competition, and evolving treatment guidelines.
Key Takeaways
- Market size constrained by declining COVID-19 hospitalization rates and competition from oral antivirals.
- Prices currently plateau with minor downward adjustments expected over the next 1-2 years.
- Long-term projections indicate a significant demand decline unless repurposed or used in future outbreaks.
- Competitive pressures and policy shifts may lead to further price reductions, especially if generic manufacturing occurs.
FAQs
Q1: Will remdesivir's price increase due to new variants?
No. Variants influence treatment strategy but do not directly impact the drug’s price unless new formulation requirements are announced.
Q2: How does the emergence of oral antivirals affect remdesivir’s pricing?
Oral antivirals offer easier administration and are preferred in outpatient settings, potentially reducing remdesivir’s demand and pressuring prices downward.
Q3: Are there regional differences in remdesivir prices?
Yes. Prices vary based on negotiated discounts, local policies, and procurement contracts across different countries and healthcare systems.
Q4: What factors influence future demand for remdesivir?
The rate of COVID-19 hospitalization, regulatory approvals for other drugs, and the evolution of treatment guidelines.
Q5: Is remdesivir likely to retain patent protection?
Remdesivir's original patent protection is expected to expire within the next 2-3 years, opening possibilities for generic production which could significantly lower prices.
References
- IQVIA. (2022). Global antiviral sales report.
- FDA. (2023). Veklury (Remdesivir) prescribing information.
- PharmacoEpi. (2023). COVID-19 antiviral market trends.
- Health Policy Watch. (2023). COVID-19 treatment landscape.
